A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.

Inclusion Criteria:

• Voluntarily participate in the study and sign the informed consent form;
• 18-65 years of age (including boundary values) ;
• Body mass index met the requirements;
• Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months;
• Meet the relevant requirements for prior medications;
• HBsAg and HBV DNA and liver function indicators meet the requirements;
• Effective contraception as required;

Exclusion Criteria:

• Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection;
• Associated liver disease;
• Any serious infection other than CHB infection requires intravenous anti-infective therapy;
• HCV RNA positive, HIV antibody positive, syphilis positive;
• Abnormal laboratory results;
• Diseases associated with vascular inflammatory conditions;
• QT interval corrected heart rate (Fridericia method) abnormal;
• History of malignancy or ongoing assessment of possible malignancy;
• History of allergies, or allergic constitution;
• Participants with recent major trauma or major surgery, or planning surgery;
• Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• Prior/current use of prohibited medications;
• Inappropriate for participation in this trial as judged by the investigator.